AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (50 + 150 mg, cumulative dose of 200 mg)
Number of subjects: 120
Study 15897671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15897671 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 120
Study 12695239 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 20
Study 12695239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10493845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=46)
Number of subjects: 151
Study 10493845 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 151
Study 8965118 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone), daily subcutaneous treatment, dosage not specified, duration not specified
Number of subjects: 0
Study 8965118 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone)
Number of subjects: 0
Study 1984496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 265
Study 1984496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 1984496 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 265
Study 6848810 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride-hydrochlorothiazide combination
Number of subjects: 0
Study 6848810 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 0
Study 6848810 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30885666 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Number of subjects: 20
Study 30885666 — intervention group
Group type: COMPARATOR
Intervention: Control group (fertile women)
Number of subjects: 20
Study 29152910 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic occluding contact lenses (OCLs)
Number of subjects: 2
Study 29152910 — intervention group
Group type: COMPARATOR
Intervention: Eye patching
Number of subjects: 2
Study 25918718 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient‐controlled analgesia (PCA) with morphine (Group 1)
Number of subjects: 34
Study 25918718 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA) with levobupivacaine (Group 2)
Number of subjects: 34
Study 23710686 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph (HRT) imaging
Number of subjects: 489
Study 23710686 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT disc area and pattern standard deviation (PSD)
Number of subjects: 489
Study 23710686 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT)
Number of subjects: 489
Study 22048172 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 0
Study 22048172 — intervention group
Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 0
Study 18694603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone (15 mg/Kg then 7 mg/Kg/day for one month)
Number of subjects: 200
Study 18694603 — intervention group
Group type: COMPARATOR
Intervention: Oral bisoprolol (2.5 mg then 2.5 mg bid indefinitely)
Number of subjects: 200
Study 18694603 — intervention group
Group type: COMPARATOR
Intervention: Oral bisoprolol
Number of subjects: 200
Study 18694603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone
Number of subjects: 200
Study 18694603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 17405996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation or suppression
Number of subjects: 2144
Study 17405996 — intervention group
Group type: COMPARATOR
Intervention: No ovarian ablation or suppression
Number of subjects: 2144
Study 15315305 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (90 mg/m2)
Number of subjects: 32
Study 15315305 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (45 mg/m2)
Number of subjects: 32
Study 11159474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocucoat (hydroxypropyl methylcellulose 2%)
Number of subjects: 40
Study 11159474 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat (sodium chondroitin sulphate 4%-sodium hyaluronate 3%)
Number of subjects: 40
Study 9757881 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic methotrexate therapy
Number of subjects: 0
Study 9757881 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingostomy
Number of subjects: 0
Study 8526970 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT alone (AMPT/placebo)
Number of subjects: 41
Study 8526970 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT plus L-dopa/carbidopa
Number of subjects: 41
Study 8526970 — intervention group
Group type: COMPARATOR
Intervention: L-dopa/carbidopa alone (placebo plus L-dopa/carbidopa)
Number of subjects: 41
Study 8526970 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone (placebo plus placebo)
Number of subjects: 41
Study 2193407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 91
Study 2193407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 91
Study 2193407 — intervention group
Group type: EXPERIMENTAL
Intervention: Diloxanide furoate (study 1)
Number of subjects: 91
Study 2193407 — intervention group
Group type: EXPERIMENTAL
Intervention: Diloxanide furoate (study 2)
Number of subjects: 91
Study 211316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestyramine (0.6 g/kg body weight)
Number of subjects: 20
Study 211316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (0.5 g/kg body weight)
Number of subjects: 20
Study 211316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestyramine and Colestipol
Number of subjects: 20
Study 31029616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus‐eluting scaffold
Number of subjects: 60
Study 25929529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy plus general practitioners' care
Number of subjects: 135
Study 25929529 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' care alone
Number of subjects: 135
Study 24196470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal first web-space approach (group D)
Number of subjects: 122
Study 24196470 — intervention group
Group type: COMPARATOR
Intervention: Medial transarticular approach (group M)
Number of subjects: 122
Study 21904959 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 21
Study 21904959 — intervention group
Group type: COMPARATOR
Intervention: Laser ablation
Number of subjects: 21
Study 19020973 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily plus exemestane 25 mg/day
Number of subjects: 157
Study 16998765 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 27
Study 16998765 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 27
Study 15249276 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 199
Study 15249276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 199
Study 15249276 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (in Study II)
Number of subjects: 199
Study 10930365 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3, 6 g/day for 9 months
Number of subjects: 40
Study 10930365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10930365 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 40
Study 9369848 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg vaginal progesterone every 48 hours
Number of subjects: 31
Study 9369848 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg vaginal progesterone every 48 hours
Number of subjects: 31
Study 1339108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 1339108 — intervention group
Group type: COMPARATOR
Intervention: Less aggressive treatment
Number of subjects: 0
Study 1339108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 1339108 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to therapy
Number of subjects: 0
Study 3909841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 60
Study 3909841 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what was administered)
Number of subjects: 60
Study 30795951 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months during aromatase inhibitor therapy)
Number of subjects: 3425
Study 30795951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo every 6 months during aromatase inhibitor therapy)
Number of subjects: 3425
Study 30795951 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 3425
Study 30795951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3425
Study 29769107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention plus email counseling
Number of subjects: 0
Study 29769107 — intervention group
Group type: COMPARATOR
Intervention: Pedometer-based intervention alone
Number of subjects: 0
Study 29769107 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study 26996580 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer exercise (ISE)
Number of subjects: 50
Study 26996580 — intervention group
Group type: COMPARATOR
Intervention: Control group (comprehensive rehabilitation therapy only)
Number of subjects: 50
Study 25219783 — intervention group
Group type: EXPERIMENTAL
Intervention: OmniGen‐AF(®)
Number of subjects: 40
Study 25219783 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 22906338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20cc of 0.5% bupivacaine)
Number of subjects: 60
Study 22906338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20cc saline)
Number of subjects: 60
Study 22906338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60
Study 21143094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil 500 (2 g daily)
Number of subjects: 18
Study 21143094 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate (initial dosage of 0.1 mg/kg/d)
Number of subjects: 18
Study 21143094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 17101259 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF group (n = 36) injected with 40 microg of fentanyl and 2% lidocaine hydrochloride with 1:200000 adrenaline
Number of subjects: 71
Study 17101259 — intervention group
Group type: COMPARATOR
Intervention: LA group (n = 35) injected with 0.9% saline instead of fentanyl
Number of subjects: 71
Study 17101259 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF group (n = 36)
Number of subjects: 71
Study 17101259 — intervention group
Group type: COMPARATOR
Intervention: LA group (n = 35)
Number of subjects: 71
Study 15911155 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate/dextromethorphan (MS/DM) combination
Number of subjects: 0
Study 15911155 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (MS)
Number of subjects: 0
Study 15911155 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titrated doses of MS/DM
Number of subjects: 0
Study 15911155 — intervention group
Group type: COMPARATOR
Intervention: Self-titrated doses of MS
Number of subjects: 0
Study 12142633 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g) during the ovulatory phase
Number of subjects: 12
Study 9449270 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 400 mg once daily
Number of subjects: 624
Study 9449270 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily
Number of subjects: 624
Study 9449270 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin 500 mg twice daily
Number of subjects: 624
Study 7840070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran-enriched test meal (12.8 g fiber) after 14 days of oat bran feeding (40 g/d)
Number of subjects: 6
Study 7840070 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15.6 g fiber/d)
Number of subjects: 6
Study 1969060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dithiocarb (DTC)
Number of subjects: 60
Study 1969060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dithiocarb (DTC)
Number of subjects: 60
Study 1969060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1969060 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC (both intravenous and oral)
Number of subjects: 60
Study 7433475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%)
Number of subjects: 0
Study 7433475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline (formulation in boric acid)
Number of subjects: 0
Study 7433475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7433475 — intervention group
Group type: COMPARATOR
Intervention: 1% Naphazoline
Number of subjects: 0
Study 31136904 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) applied on the biceps brachii at the contralateral limb
Number of subjects: 40
Study 31136904 — intervention group
Group type: COMPARATOR
Intervention: No taping (control)
Number of subjects: 40
Study 27988093 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthen your ankle App
Number of subjects: 220
Study 27988093 — intervention group
Group type: COMPARATOR
Intervention: Printed Booklet
Number of subjects: 220
Study 25287366 — intervention group
Group type: COMPARATOR
Intervention: Conventional monovision
Number of subjects: 59
Study 25287366 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed monovision
Number of subjects: 59
Study 24084051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake
Number of subjects: 234
Study 24084051 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting the Recommended Dietary Allowance (RDA) for magnesium
Number of subjects: 234
Study 23560243 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal smear group (259 subjects)
Number of subjects: 644
Study 23560243 — intervention group
Group type: COMPARATOR
Intervention: Blood specimen group (385 subjects)
Number of subjects: 644
Study 23560243 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric subjects (113 out of 491)
Number of subjects: 644
Study 23560243 — intervention group
Group type: COMPARATOR
Intervention: Adult subjects (25 out of 167)
Number of subjects: 644
Study 19132853 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring system (CGMS) with alarm function activated
Number of subjects: 1001
Study 19132853 — intervention group
Group type: COMPARATOR
Intervention: Real-time continuous glucose monitoring system (CGMS) without alarm function activated
Number of subjects: 1001
Study 19132853 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring system (CGMS)
Number of subjects: 1001
Study 17230105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve harvesting
Number of subjects: 14
Study 17230105 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 14
Study 16083185 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract (Kamillosan M) spray, 10 puffs of total 370 mg
Number of subjects: 161
Study 16083185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lubrication)
Number of subjects: 161
Study 16083185 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract (Kamillosan M) spray
Number of subjects: 161
Study 11520381 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale - Telephone version (GDS-T)
Number of subjects: 252
Study 11520381 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale - Personal version (GDS-P)
Number of subjects: 252
Study 9541761 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients referred by a physician for possible study entry
Number of subjects: 88881
Study 9541761 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiographic laboratory record screening
Number of subjects: 88881
Study 9541761 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography (ECG) laboratory patient records
Number of subjects: 88881
Study 8187120 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg daily
Number of subjects: 48
Study 8187120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3670972 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions of buffy coats from single units of whole blood (0.1 to 0.9 X 10(9) polymorphonuclear leukocytes per kilogram) given daily until ANC > 1,500/microL
Number of subjects: 25
Study 3670972 — intervention group
Group type: COMPARATOR
Intervention: Nontransfusion (control group)
Number of subjects: 25
Study 31834381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking heaviness (G0)
Number of subjects: 0
Study 31834381 — intervention group
Group type: COMPARATOR
Intervention: Maternal non-smoking (G0)
Number of subjects: 0
Study 31834381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking heaviness (G0) on grandchild's (G2) birthweight
Number of subjects: 0
Study 29679914 — intervention group
Group type: EXPERIMENTAL
Intervention: CAAT‐training (Cannabis Approach‐Avoidance Task Training)
Number of subjects: 80
Study 29679914 — intervention group
Group type: COMPARATOR
Intervention: CAAT‐sham training
Number of subjects: 80
Study 28610969 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-turn gait speed
Number of subjects: 93
Study 28610969 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-forward gait speed
Number of subjects: 93
Study 28610969 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance tolerance limit (BTL)
Number of subjects: 93
Study 23841567 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health intervention including individually tailored instructions for oral and/or denture hygiene, relief of dry mouth symptoms, decrease of sugar-use frequency, use of fluoride, xylitol or antimicrobial products, and professional tooth cleaning
Number of subjects: 279
Study 23841567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 279
Study 22798151 — intervention group
Group type: EXPERIMENTAL
Intervention: OTI + PP
Number of subjects: 29
Study 22798151 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 29
Study 20364888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress session (exposure to a brief standardized psychosocial laboratory stressor)
Number of subjects: 29
Study 20364888 — intervention group
Group type: COMPARATOR
Intervention: Control session (stress-free)
Number of subjects: 29
Study 20364888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress session
Number of subjects: 29
Study 18006073 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of completed suicide
Number of subjects: 4001
Study 18006073 — intervention group
Group type: COMPARATOR
Intervention: No family history of completed suicide
Number of subjects: 4001
Study 15734851 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycemia
Number of subjects: 24
Study 15734851 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp
Number of subjects: 24
Study 12850465 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (intervention group [IG], n = 44)
Number of subjects: 91
Study 12850465 — intervention group
Group type: COMPARATOR
Intervention: Control (nonintervention group [NG], n = 47)
Number of subjects: 91
Study 10097781 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental case managers
Number of subjects: 0
Study 10097781 — intervention group
Group type: COMPARATOR
Intervention: Control case managers
Number of subjects: 0
Study 10097781 — intervention group
Group type: EXPERIMENTAL
Intervention: Client acuity (measured by ADL functioning and prior hospital use)
Number of subjects: 0
Study 8866926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate 200 mg orally (three tablets)
Number of subjects: 6
Study 1817051 — intervention group
Group type: EXPERIMENTAL
Intervention: herbal extracts
Number of subjects: 50
Study 1817051 — intervention group
Group type: COMPARATOR
Intervention: placebo preparation
Number of subjects: 50
Study 7068863 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training group
Number of subjects: 48
Study 7068863 — intervention group
Group type: COMPARATOR
Intervention: Counselor intervention group
Number of subjects: 48
Study 7068863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 30882150 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ+PQ (Chloroquine + Primaquine: 0.25 mg base/kg/day for 14 days)
Number of subjects: 206
Study 30882150 — intervention group
Group type: COMPARATOR
Intervention: CQ (Chloroquine: 25 mg base/kg given over 3 days)
Number of subjects: 206
Study 27746233 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (500 mL drink containing 40 g of inulin)
Number of subjects: 29
Study 27746233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (500 mL drink containing 40 g of fructose)
Number of subjects: 29
Study 27746233 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (500 mL drink containing 40 g of glucose)
Number of subjects: 29
Study 27746233 — intervention group
Group type: COMPARATOR
Intervention: Fructose
Number of subjects: 29
Study 27746233 — intervention group
Group type: COMPARATOR
Intervention: Inulin
Number of subjects: 29
Study 27746233 — intervention group
Group type: COMPARATOR
Intervention: Fructose and inulin
Number of subjects: 29
Study 27746233 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study 26554558 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin once daily
Number of subjects: 100
Study 26554558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23928079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil size measured by a bedside camera
Number of subjects: 0